在三阴性乳腺癌模型中,MCAK 抑制剂诱导质积分
John C Smith1, Stefan Husted2, Jay Pilrose3
1Medical Sciences, Indiana School of Medicine-Bloomington, Bloomington, IN 47405, USA.
Cancers
|July 14, 2023
概括
向MCAK,一种限制异形积分的蛋白质,显示出治疗三阴性乳腺癌 (TNBC) 的前景. 抑制MCAK使TNBC细胞对帕克利塔塞尔敏感,并可作为预后生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 三重阴性乳腺癌 (TNBC) 的标准治疗方法是使用帕克利塔塞尔,这是一种诱导动脉积分的微管毒素.
- 虽然最初是有效的,但帕克利塔克塞尔治疗往往导致剂量限制的外围神经病变和耐药瘤的发展.
- 确定新的治疗点对于克服耐药性和改善TNBC治疗结果至关重要.
研究的目的:
- 调查微管脱聚化素 (MCAK) 作为TNBC中潜在的治疗点的作用.
- 为了确定MCAK抑制是否可以使TNBC细胞对帕克利塔塞尔敏感并克服耐药性.
- 评估MCAK作为TNBC中的预后生物标志物.
主要方法:
- 对公开可用的数据集进行分析,以评估MCAK表达及其与TNBC预后的相关性.
- 在TNBC细胞系中MCAK的体外淘汰,以评估其对帕克利塔塞尔敏感性的影响.
- 化合物库的高通量选,以使用FRET和基于图像的测试来识别MCAK抑制剂.
主要成果:
- 在TNBC中,MCAK被上调,并与较差的患者预后有关.
- 在TNBC细胞中,MCAK倒置显著降低了帕克利塔塞尔IC50,但没有影响正常细胞.
- 确定了三种新型MCAK抑制剂,它们诱导了形,降低了TNBC细胞存活率,并使细胞对帕克利塔塞尔敏感.
结论:
- MCAK是TNBC的一个有前途的治疗标,有可能克服帕克利塔塞尔耐药性.
- 抑制MCAK是一种可行的策略,可以提高现有化疗的疗效.
- MCAK可能成为三阴性乳腺癌的宝贵预后生物标志物.
相关概念视频
01:21Nondisjunction
3.9K
Nondisjunction is the failure of homologous chromosomes or sister chromatids to separate correctly and move to the opposite poles of the cells. This produces daughter cells with abnormal chromosome numbers. Nondisjunction is common during anaphase I or anaphase II of meiosis. Mutations in synaptonemal complex proteins that attach homologous chromosomes increase the chances of nondisjunction in anaphase I of meiosis I. In contrast, mutations in topoisomerases and condensins that hold...
3.9K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K